Eli Lilly hits $1 trillion market value, a first in health care, as Novo Nordisk tumbles
The pharmaceutical giant Eli Lilly's stock has been riding the skyrocketing demand for its weight loss injection Zepbound and diabetes treatment Mounjaro.
The pharmaceutical giant Eli Lilly’s stock has been riding the skyrocketing demand for its weight loss injection Zepbound and diabetes treatment Mounjaro.
